Publicaciones en colaboración con investigadores/as de Hospital Universitario de la Princesa (30)

2024

  1. BRIVA-ONE study: 12-month outcomes of brivaracetam monotherapy in clinical practice

    Epilepsia Open

  2. Long-term safety of OnabotulinumtoxinA treatment in chronic migraine patients: a five-year retrospective study

    Frontiers in Neurology , Vol. 15

  3. Migraine treatment consensus document of the Spanish Society of Neurology (SEN), Spanish Society of Family and Community Medicine (SEMFYC), Society of Primary Care Medicine (SEMERGEN) and Spanish Association of Migraine and Headache (AEMICE) on migraine treatment

    Medicina Clinica, Vol. 163, Núm. 4, pp. 208.e1-208.e10

  4. Nueva era terapéutica para el ataque de migraña con los recientemente aprobados anticuerpos monoclonales, ditanes y gepantes

    Revista de neurologia, Vol. 78, Núm. 2, pp. 47-57

  5. Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

    Journal of neurology, neurosurgery, and psychiatry, Vol. 95, Núm. 10, pp. 927-937

2023

  1. Hemihypomimia in Parkinson’s disease: an under-recognized clinical sign?

    Journal of Neurology

  2. Medical help-seeking intentions among patients with early Alzheimer’s disease

    Frontiers in Psychiatry, Vol. 14

  3. Recomendaciones de consenso para el tratamiento de la prevención de la migraña

    Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. 246-253

  4. Staging Parkinson's Disease According to the MNCD (Motor/Non-motor/Cognition/Dependency) Classification Correlates with Disease Severity and Quality of Life

    Journal of Parkinson's disease, Vol. 13, Núm. 3, pp. 379-402

  5. [Translated article] Consensus recommendations on the preventive treatment of migraine

    Farmacia Hospitalaria, Vol. 47, Núm. 6, pp. T246-T253

2022

  1. Awareness of Diagnosis in Persons with Early-Stage Alzheimer’s Disease: An Observational Study in Spain

    Neurology and Therapy, Vol. 11, Núm. 3, pp. 1183-1192

  2. Calcitonin gene–related peptide in migraine: from pathophysiology to treatment

    Neurologia, Vol. 37, Núm. 5, pp. 390-402

  3. Cutaneous Allodynia in Migraine: A Narrative Review

    Frontiers in Neurology, Vol. 12

  4. Outcomes from a Spanish Expanded Access Program on cannabidiol treatment in pediatric and adult patients with epilepsy

    Epilepsy and Behavior, Vol. 137

  5. Quality of Life and the Experience of Living with Early-Stage Alzheimer's Disease

    Journal of Alzheimer's disease : JAD, Vol. 90, Núm. 2, pp. 719-726

  6. Trial of Prasinezumab in Early-Stage Parkinson's Disease

    New England Journal of Medicine, Vol. 387, Núm. 5, pp. 421-432

2021

  1. Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease

    Neurology, Vol. 97, Núm. 14, pp. E1367-E1381

  2. Present and future of parkinson’s disease in Spain: Parkinson-2030 delphi project

    Brain Sciences, Vol. 11, Núm. 8

  3. Safety of anti-CGRP monoclonal antibodies in patients with migraine during the COVID-19 pandemic: Present and future implications

    Neurologia, Vol. 36, Núm. 8, pp. 611-617

2020

  1. Evaluation of the concomitant use of oral preventive treatments and onabotulinumtoxinA in chronic migraine: the PREVENBOX study

    European Journal of Neurology, Vol. 27, Núm. 10, pp. 2102-2108